Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 02, 2026, titled "Glenmark Advances Multi-Country Phase 3 Clinical Trial of Trastuzumab rezetecan in Platinum-Resistant Ovarian Cancer".
Glenmark Pharmaceuticals Limited Press Release Jul 02 2026
Earlier from Glenmark Pharmaceuticals
- Glenmark Pharmaceuticals Limited Press Release Jun 17 2026
- Glenmark Pharmaceuticals Limited Press Release Jun 11 2026